McKesson Corporation (MCK) Stock Analysis

McKesson’s primary competitive advantage is its unmatched scale in pharmaceutical distribution, handling roughly one-third of all U.S. prescription medicines daily. This scale enables superior purchasing power, supply chain reliability (99.9% delivery accuracy), and working capital efficiency—McKesson operates with a negative cash conversion cycle, supporting robust free cash flow despite industry-low margins (net margin ~1.2%).

The company’s moat is reinforced by high regulatory barriers and switching costs. Compliance with complex drug-tracking laws (e.g., DSCSA) and the capital intensity of national distribution networks make market entry prohibitively expensive for new competitors. Customer relationships are sticky; major clients like CVS account for 24% of revenue, and contract transitions are operationally disruptive.

McKesson distinguishes itself from peers—Cencora (formerly AmerisourceBergen) and Cardinal Health—by layering higher-margin specialty services atop its distribution backbone. Its Oncology & Multispecialty segment grew revenue 31% and operating profit 53% in FY26, outpacing the core business and rivals. The US Oncology Network and Ontada (real-world data/analytics) embed McKesson deeper into provider workflows, making it more than a logistics vendor.

Prescription Technology Solutions (RxTS) further differentiates McKesson, connecting over 50,000 pharmacies and 1 million providers to address medication access and affordability—saving patients $10 billion and preventing 12 million prescription abandonments in FY25.

While customer concentration and regulatory risk remain, McKesson’s scale, integrated specialty platforms, and technology-enabled services create durable advantages that are difficult for competitors to replicate.